DK2739153T3 - Behandling af brystkræft - Google Patents
Behandling af brystkræft Download PDFInfo
- Publication number
- DK2739153T3 DK2739153T3 DK12846720.6T DK12846720T DK2739153T3 DK 2739153 T3 DK2739153 T3 DK 2739153T3 DK 12846720 T DK12846720 T DK 12846720T DK 2739153 T3 DK2739153 T3 DK 2739153T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- breast cancer
- cells
- inhibitors
- dht
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (4)
1. Forbindelse eller et farmaceutisk acceptabelt salt deraf til anvendelse i behandling af triple-negativ brystkræft, hvor forbindelsen er enzalutamid:
hvor celler af den triple-negative brystkræft udtrykker en androgen-receptor.
2. Forbindelsen eller saltet til anvendelse ifølge krav 1, hvor den triple-negative brystkræft er en undertype valgt fra gruppen bestående af basal-lignende type 1 (BL1), basal-lignende type 2 (BL2), immunomodulerende (IM), mesenkymal (M), mesenkymal stam-lignende (MSL), og luminal androgen-receptor-(LAR)-undertyper.
3. Forbindelsen eller saltet til anvendelse ifølge krav 1, hvor celler af den triple-negative brystkræft omfatter en BRCA1 -mutation.
4. Forbindelsen eller saltet til anvendelse ifølge krav 1, hvor forbindelsen eller saltet er til anvendelse i kombination med kemoterapier eller andre terapeutiske midler, såsom PI3K/mTOR-inhibitorer, EGFR-inhibitorer, angiogenese-inhibitorer, cytotoksiske midler, vacciner, Bcr-Abl-kinase-inhibitorer, knoglemålrettede midler, GnRH-analoger, anthracycliner, PARP-inhibitorer, Akt-inhibitorer eller Her3-inhibitorer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513361P | 2011-07-29 | 2011-07-29 | |
| PCT/US2012/048471 WO2013066440A1 (en) | 2011-07-29 | 2012-07-27 | Treatment of breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2739153T3 true DK2739153T3 (da) | 2018-12-03 |
Family
ID=48192564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12846720.6T DK2739153T3 (da) | 2011-07-29 | 2012-07-27 | Behandling af brystkræft |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9517229B2 (da) |
| EP (4) | EP3791724A1 (da) |
| JP (2) | JP6158180B2 (da) |
| KR (1) | KR101923250B1 (da) |
| CN (1) | CN103997894B (da) |
| BR (1) | BR112014002200A2 (da) |
| CA (1) | CA2843417C (da) |
| CY (1) | CY1121038T1 (da) |
| DK (1) | DK2739153T3 (da) |
| EA (1) | EA028452B1 (da) |
| ES (1) | ES2696074T3 (da) |
| HK (2) | HK1198867A1 (da) |
| HU (1) | HUE040524T2 (da) |
| MX (1) | MX359664B (da) |
| PL (1) | PL2739153T3 (da) |
| PT (1) | PT2739153T (da) |
| SI (1) | SI2739153T1 (da) |
| WO (1) | WO2013066440A1 (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066440A1 (en) * | 2011-07-29 | 2013-05-10 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| ES2836424T3 (es) | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| AU2014254058B2 (en) * | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer |
| JP6945587B2 (ja) * | 2013-11-07 | 2021-10-06 | デシフェラ ファーマシューティカルズ，エルエルシー | ガンの処置に有用なｔｉｅ２キナーゼの阻害方法 |
| CN108464981B (zh) * | 2013-11-07 | 2022-06-24 | 德西费拉制药有限责任公司 | 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 |
| EP3148336B1 (en) * | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| US10196693B2 (en) * | 2014-12-12 | 2019-02-05 | Medivation Prostate Therapeutics Llc | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
| CN107530291A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 双重负载的脂质体药物制剂 |
| US9895313B2 (en) | 2015-03-03 | 2018-02-20 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| CN104857517B (zh) * | 2015-05-14 | 2018-04-27 | 南京海纳医药科技股份有限公司 | 一种恩杂鲁胺软胶囊及其制备方法 |
| US9963433B2 (en) * | 2016-01-29 | 2018-05-08 | Wayne State University | Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor |
| CN110996955A (zh) | 2017-06-22 | 2020-04-10 | 细胞基因公司 | 以乙型肝炎病毒感染为特征的肝细胞癌的治疗 |
| JOP20200076A1 (ar) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals Inc | مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال |
| CN107987055A (zh) * | 2017-12-19 | 2018-05-04 | 刘秀云 | 硫代咪唑二酮类雄激素受体拮抗剂及其用途 |
| CN111818915B (zh) | 2018-01-31 | 2024-05-24 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| CA3121199A1 (en) * | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP4013412A1 (en) | 2019-08-12 | 2022-06-22 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| KR20220123057A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 비정질 키나아제 억제제 제형 및 이의 사용 방법 |
| EP4084779A1 (en) | 2019-12-30 | 2022-11-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| EP3970721A1 (en) * | 2005-05-13 | 2022-03-23 | The Regents Of The University Of California | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer |
| WO2007061876A2 (en) | 2005-11-23 | 2007-05-31 | University Of Utah Research Foundation | Methods and compositions involving intrinsic genes |
| EP2004181B3 (en) * | 2006-03-27 | 2023-05-24 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| US8110594B2 (en) | 2006-03-29 | 2012-02-07 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
| CA2966280A1 (en) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
| US8450290B2 (en) | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
| WO2009114534A1 (en) | 2008-03-14 | 2009-09-17 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| WO2009158143A1 (en) | 2008-05-30 | 2009-12-30 | The University Of North Carolina At Chapel Hill | Gene expression profiles to predict breast cancer outcomes |
| EP2400847B1 (en) * | 2009-02-24 | 2014-12-17 | Medivation Prostate Therapeutics, Inc. | Specific diarylthiohydantoin compounds |
| US8710086B2 (en) | 2009-04-09 | 2014-04-29 | Medivation Technologies, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof |
| US8507195B2 (en) * | 2009-08-20 | 2013-08-13 | The Regents Of The University Of Colorado | MiRNAs dysregulated in triple-negative breast cancer |
| EP2485804A4 (en) | 2009-10-07 | 2015-07-29 | Medivation Technologies Inc | SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS |
| AU2012229123B2 (en) | 2011-03-15 | 2017-02-02 | British Columbia Cancer Agency Branch | Methods of treating breast cancer with anthracycline therapy |
| WO2013066440A1 (en) * | 2011-07-29 | 2013-05-10 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
| AU2012345789B2 (en) | 2011-11-30 | 2018-02-15 | British Columbia Cancer Agency Branch | Methods of treating breast cancer with taxane therapy |
| EP2888594B1 (en) | 2012-08-23 | 2018-08-15 | The Regents of the University of Colorado, a body corporate | Method for determining breast cancer treatment |
| US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| WO2014075067A1 (en) | 2012-11-12 | 2014-05-15 | Nanostring Technologies, Inc. | Methods to predict breast cancer outcome |
| US10679730B2 (en) | 2013-05-28 | 2020-06-09 | The University Of Chicago | Prognostic and predictive breast cancer signature |
| US10196693B2 (en) | 2014-12-12 | 2019-02-05 | Medivation Prostate Therapeutics Llc | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
-
2012
- 2012-07-27 WO PCT/US2012/048471 patent/WO2013066440A1/en active Application Filing
- 2012-07-27 SI SI201231453T patent/SI2739153T1/sl unknown
- 2012-07-27 CN CN201280048192.2A patent/CN103997894B/zh active Active
- 2012-07-27 EP EP20191500.6A patent/EP3791724A1/en not_active Withdrawn
- 2012-07-27 ES ES12846720T patent/ES2696074T3/es active Active
- 2012-07-27 MX MX2014001218A patent/MX359664B/es active IP Right Grant
- 2012-07-27 EA EA201400178A patent/EA028452B1/ru not_active IP Right Cessation
- 2012-07-27 EP EP12846720.6A patent/EP2739153B1/en active Active
- 2012-07-27 BR BR112014002200A patent/BR112014002200A2/pt not_active Application Discontinuation
- 2012-07-27 KR KR1020147005617A patent/KR101923250B1/ko active IP Right Grant
- 2012-07-27 DK DK12846720.6T patent/DK2739153T3/da active
- 2012-07-27 US US14/236,036 patent/US9517229B2/en active Active
- 2012-07-27 JP JP2014523048A patent/JP6158180B2/ja active Active
- 2012-07-27 PL PL12846720T patent/PL2739153T3/pl unknown
- 2012-07-27 CA CA2843417A patent/CA2843417C/en active Active
- 2012-07-27 HU HUE12846720A patent/HUE040524T2/hu unknown
- 2012-07-27 PT PT12846720T patent/PT2739153T/pt unknown
- 2012-07-27 EP EP18190012.7A patent/EP3430907A1/en not_active Withdrawn
- 2012-07-27 EP EP19187649.9A patent/EP3610731A1/en not_active Withdrawn
-
2014
- 2014-12-10 HK HK14112422.7A patent/HK1198867A1/xx unknown
-
2015
- 2015-02-11 HK HK15101529.1A patent/HK1201413A1/xx unknown
-
2016
- 2016-12-09 US US15/373,914 patent/US10111861B2/en active Active
-
2017
- 2017-03-31 JP JP2017072819A patent/JP2017141269A/ja active Pending
-
2018
- 2018-10-24 US US16/168,896 patent/US20190262315A1/en not_active Abandoned
- 2018-11-08 CY CY181101174T patent/CY1121038T1/el unknown
-
2020
- 2020-01-22 US US16/749,133 patent/US20210069154A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2739153T3 (da) | Behandling af brystkræft | |
| AU2016256471B2 (en) | Methods of treating cancer | |
| CA2861056A1 (en) | Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders | |
| US11224608B2 (en) | Compounds and methods for treating cancer | |
| EP4119557A1 (en) | Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound | |
| BR112020023204A2 (pt) | composições que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso dos mesmos | |
| KR20210010524A (ko) | 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물 | |
| KR101847252B1 (ko) | 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| RU2813111C2 (ru) | Фармацевтическая комбинация, содержащая tno155 и рибоциклиб | |
| KR102676629B1 (ko) | 암을 치료하는 방법 | |
| WO2022238706A1 (en) | Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer | |
| WO2021048418A1 (en) | Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma | |
| WO2018195202A1 (en) | Compositions and methods for the treatment of cancer | |
| CN112533600A (zh) | 用于治疗小细胞肺癌的喹啉衍生物 | |
| WO2011152515A1 (ja) | インドール化合物を含有する抗腫瘍剤 |